AMARIN CORP PLC\UK Adjustments to Additional Paid in Capital, Other
AMARIN CORP PLC\UK (AMRN) reported Adjustments to Additional Paid in Capital, Other of -$10.10 million for the 12-month period ending 2014-12-31, per its 10-K filed 2015-03-03.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalOther · last filed 2015-03-03
- AMARIN CORP PLC\UK adjustments to additional paid in capital, other for the quarter ending 2014-12-31 was $0.00.
- AMARIN CORP PLC\UK adjustments to additional paid in capital, other for the quarter ending 2014-09-30 was $0.00.
- AMARIN CORP PLC\UK adjustments to additional paid in capital, other for the quarter ending 2012-12-31 was $0.00, a 100.00% decline year-over-year.
- AMARIN CORP PLC\UK adjustments to additional paid in capital, other for the quarter ending 2012-09-30 was $11.60M, a 44.75% decline year-over-year.
- AMARIN CORP PLC\UK adjustments to additional paid in capital, other for fiscal 2014 was -$10.10M, a 42183.33% decline from fiscal 2013.
- AMARIN CORP PLC\UK adjustments to additional paid in capital, other for fiscal 2013 was $24.00K, a 99.98% decline from fiscal 2012.
- AMARIN CORP PLC\UK adjustments to additional paid in capital, other for fiscal 2012 was $103.89M, a 19.79% decline from fiscal 2011.
- AMARIN CORP PLC\UK adjustments to additional paid in capital, other for fiscal 2011 was $129.52M, a 480.35% increase from fiscal 2010.
| Period end | Adjustments to Additional Paid in Capital, Other 3 month | Adjustments to Additional Paid in Capital, Other 6 month | Adjustments to Additional Paid in Capital, Other 9 month | Adjustments to Additional Paid in Capital, Other 12 month |
|---|---|---|---|---|
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-03 | $0.00 derived: sum of 2 quarters · filed 2015-03-03 | -$10.10M 10-K · filed 2015-03-03 | |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | -$10.10M 10-Q · filed 2014-11-06 | ||
| 2014-06-30 | -$10.10M 10-Q · filed 2014-08-07 | |||
| 2013-12-31 | $24.00K 10-K · filed 2015-03-03 | |||
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-03 | $11.60M derived: sum of 2 quarters · filed 2015-03-03 | $103.56M derived: sum of 3 quarters · filed 2015-03-03 | $103.89M 10-K · filed 2015-03-03 |
| 2012-09-30 | $11.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | $103.56M derived: sum of 2 quarters · filed 2013-11-07 | $103.89M 10-Q · filed 2013-11-07 | $103.94M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-06-30 | $91.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-08 | $92.28M 10-Q · filed 2013-08-08 | $92.34M derived: sum of 3 quarters · filed 2014-02-27 | $113.34M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-03-31 | $321.00K 10-Q · filed 2013-05-09 | $380.00K derived: sum of 2 quarters · filed 2014-02-27 | $21.38M derived: sum of 3 quarters · filed 2014-02-27 | |
| 2011-12-31 | $59.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-27 | $21.06M derived: sum of 2 quarters · filed 2014-02-27 | $129.52M 10-K · filed 2014-02-27 | |
| 2011-09-30 | $21.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-08 | $129.46M 10-Q · filed 2011-11-08 | ||
| 2011-06-30 | $108.46M 10-Q · filed 2011-08-09 | |||
| 2010-12-31 | $17.68M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-28 | $20.36M derived: sum of 2 quarters · filed 2013-02-28 | $22.32M 10-K · filed 2013-02-28 | |
| 2010-09-30 | $2.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-08 | $4.64M 10-Q · filed 2011-11-08 | ||
| 2010-06-30 | $1.95M 10-Q · filed 2011-08-09 | |||
| 2009-12-31 | $5.33M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |